Interaction between rifabutin and human immunodeficiency virus type 1: inhibition of replication, cytopathic effect, and reverse transcriptase in vitro.
Rifabutin (ansamycin; LM427), a semisynthetic rifamycin derivative, inhibits the replication of human immunodeficiency virus type 1, the virus etiologically linked to acquired immunodeficiency syndrome. The inhibition of virus production was observed in human immunodeficiency virus type 1-infected peripheral blood mononuclear cells both by reverse transcriptase assay and virus-antigen assay. In addition, rifabutin effectively reduced human immunodeficiency virus type 1-associated cytopathic effect to OKT4-positive cells. Virion-associated reverse transcriptase was also markedly inhibited by rifabutin. The inhibitory dose of rifabutin was nontoxic to lymphoid cells, which further suggests that it might serve as a useful agent in the therapeutic modalities of acquired immunodeficiency syndrome.
Anand
R
R
AIDS Program, Centers for Disease Control, Atlanta, Georgia 30333.
Moore
J L
JL
Curran
J W
JW
Srinivasan
A
A
D002460:Cell Line; D002478:Cells, Cultured; D055598:Chemical Phenomena; D002621:Chemistry; D003588:Cytopathogenic Effect, Viral; D006678:HIV / Q000187:drug effects* / Q000201:enzymology / Q000502:physiology; D006801:Humans; D009504:Neutrophils / Q000382:microbiology; D018894:Reverse Transcriptase Inhibitors; D017828:Rifabutin; D012294:Rifamycins / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
D018894:Reverse Transcriptase Inhibitors; D012294:Rifamycins; D017828:Rifabutin